<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610464</url>
  </required_header>
  <id_info>
    <org_study_id>TRI102-PPK-300</org_study_id>
    <nct_id>NCT03610464</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years</brief_title>
  <official_title>Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years With Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tris Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tris Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the plasma amphetamine concentration/time profile
      of amphetamine extended release oral suspension in children aged 4 to 5 years with
      attention-deficit/hyperactivity disorder, following a single 2.5 mg dose of amphetamine
      extended release oral suspension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DYANAVEL® XR is an extended-release oral suspension that contains 2.5 mg/mL amphetamine base
      (amphetamine extended-release oral suspension; AMPH EROS). Drug-resin complexation is formed
      with the amphetamine and sodium polystyrene sulfonate, an ion exchange resin. The extended
      release feature of the product is achieved by coating a portion of the drug/resin complexes
      with an extended release coating. AMPH EROS contains approximately a 3.2:1 ratio of
      d-amphetamine compared to l-amphetamine.

      The objective of this study was to evaluate the plasma amphetamine concentration/time profile
      of AMPH EROS in children aged 4 to 5 years with attention-deficit/hyperactivity disorder,
      following a single 2.5 mg dose of AMPH EROS.

      These data will guide appropriate dosing in planned safety and efficacy studies with AMPH
      EROS in a preschool population with attention-deficit/hyperactivity disorder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This was an open-label, single-site, single-dose one-period, one-treatment study in 5 pediatric subjects diagnosed with ADHD, otherwise healthy. Subjects received a single, 1 mL dose of AMPH EROS 2.5 mg/mL, from which PK was assessed over a 28 hour period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of d- and L-amphetamine</measure>
    <time_frame>0-28 hours postdose</time_frame>
    <description>Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Study patients (AMPH EROS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphetamine Extended Release Suspension [Dyanavel]</intervention_name>
    <description>1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
    <arm_group_label>Study patients (AMPH EROS)</arm_group_label>
    <other_name>DYANAVEL XR, amphetamine extended release oral suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 4 to 5 years at the time of enrollment into this study;

          2. Body weight ≥ 28 lb. at screening visit;

          3. Diagnosed with ADHD by a psychiatrist, psychologist, developmental pediatrician,
             pediatrician, or an experienced licensed allied health professional approved by the
             Sponsor by using the DSM-5 criteria and supported by a structured Kiddie-Schedule for
             Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL)
             interview, administered at the Screening Visit (Visit 0);

          4. Provide written informed consent (parent/guardian) prior to participation in the
             study.

        Exclusion Criteria:

          1. Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of
             specific phobias, learning disorders, motor skills disorders, communication
             disorders,oppositional defiant disorder, elimination disorders, and sleep disorders

          2. History of chronic medical illnesses including seizure disorder (excluding a history
             of febrile seizures), moderate to severe hypertension, untreated thyroid disease,
             known structural cardiac disorders, serious cardiac conditions, serious arrhythmias,
             cardiomyopathy and known family history of sudden death

          3. Known history or presence of significant renal or hepatic disease, as indicated by
             clinical laboratory assessment (liver function test results ≥ 2 times the upper limit
             of normal, blood urea nitrogen, or creatinine)

          4. Clinically significant (CS) abnormal ECG or cardiac findings on physical examination
             (including the presence of a pathologic murmur)

          5. Use of the following medications within 30 days of dosing:

               -  MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine,
                  tranylcypromine);

               -  Tricyclic Antidepressants (e.g. Desipramine, protriptyline);

          6. Use of the following medications within 3 days of dosing

               -  Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid
                  HCl, ascorbic acid);

               -  Urinary acidifying agents (e.g., ammonium chloride, sodium acid
                  phosphate,methenamine salts);

          7. Use of atomoxetine within 14 days of dosing

          8. Planned use of prohibited drugs or agents from the screening visit through the end of
             the study. Medications used to support sleep may be acceptable with the written
             approval of the sponsor or medical monitor

          9. Abnormal CS laboratory test value at screening that, in the opinion of the sponsor or
             medical monitor, would preclude study participation

         10. Known history of allergy/hypersensitivity to amphetamine or any of the components of
             AMPH EROS, heparin flush and topical anesthetics

         11. Parent or guardian's inability or unwillingness to follow directions of the
             Investigator or study research staff

         12. Any uncontrolled medical condition that in the opinion of the Investigator would
             preclude study participation

         13. History of significant illness requiring hospitalization, or surgery requiring
             anesthetics within 30 days of dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pardo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tris Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>June 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2019</results_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03610464/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Patients (AMPH EROS)</title>
          <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
Amphetamine Extended Release Suspension [Dyanavel]: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Study Patients (AMPH EROS)</title>
          <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
Amphetamine Extended Release Suspension [Dyanavel]: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentrations of d- and L-amphetamine</title>
        <description>Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose.</description>
        <time_frame>0-28 hours postdose</time_frame>
        <population>intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma Concentration of d-Amphetamine</title>
            <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
Amphetamine Extended Release Suspension [Dyanavel]: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
          </group>
          <group group_id="O2">
            <title>Plasma Concentration of l-Amphetamine</title>
            <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
Amphetamine Extended Release Suspension [Dyanavel]: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of d- and L-amphetamine</title>
          <description>Plasma Concentration of d- and l-amphetamine measured at 0, 1, 3, 4, 6, 8, 10, 12, and 28 hours postdose.</description>
          <population>intention to treat population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.0"/>
                    <measurement group_id="O2" value="1.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="2.2"/>
                    <measurement group_id="O2" value="6.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="2.5"/>
                    <measurement group_id="O2" value="6.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="3.2"/>
                    <measurement group_id="O2" value="5.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="2.2"/>
                    <measurement group_id="O2" value="5.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="3.3"/>
                    <measurement group_id="O2" value="4.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="3.2"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.7"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours post-dose. Pharmacokinetics study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Patients (AMPH EROS)</title>
          <description>All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
Amphetamine Extended Release Suspension [Dyanavel]: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Pardo MD</name_or_title>
      <organization>Tris Pharma, Inc.</organization>
      <phone>16107502210</phone>
      <email>apardo@trispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

